1639 completed, 970 unknown, 614 recruiting, 271 terminated. 1196 Phase 2, 842 Not applicable, 723 Phase 1, 417 Phase 3, 153 Phase 4.
Follow Stomach Diseases: new trials by email Literature Review of Stomach Diseases trials Research Report on Stomach Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma Pembrolizumab and either Capcecitabine + Oxaliplatin or Oxaliplatin+Leucovorin + 5-fluorouracil - Gastric Cancer, Gastroesophageal-junction Cancer | Phase 3 | Not yet recruiting | Transcenta Therapeutics (Hangzhou) Co., Ltd. | 820 | 2027-06-30 | 2026-09-29 |
| Effect Of Percutaneous Electrical Nerve Field Stimulation on Symptom Control/Nervous System Activity in Patients w/Diabetes Types 1/2 PERCUTANEOUS ELECTRICAL FIELD NERVE STIMULATION, Sham percutaneous electrical nerve field stimulation - Diabetes, Gastroparesis | Not applicable | Not yet recruiting | Indiana University | 60 | 2027-02-10 | 2026-10-01 |
| A Trial of ONO-4578 Versus Placebo in Combination With Nivolumab and Chemotherapy in Participants With Gastric Cancer, Esophagogastric Junction Cancer, or Esophageal Adenocarcinoma ONO-4578, Placebo, Nivolumab - Gastric Cancer, Esophagogastric Junction Cancer | Phase 3 | Not yet recruiting | Ono Pharmaceutical Co., Ltd. | 600 | 2027-02-01 | 2026-09-14 |
| Combination of CT and Ultrasound Radiomics Combined With Liquid Biopsy to Predict Neoadjuvant Chemotherapy Response in Patients With Locally Advanced Gastric Cancer Gastric Cancer | Not yet recruiting | Liu Yang | 300 | 2027-02-01 | 2026-07-13 | |
| Zolbetuximab and Other Cancer Treatments in People With Advanced Gastric or GEJ Cancer in Clinical Practice (RADIANCE) Zolbetuximab Exposure, Platinum-based Chemotherapy Exposure, 1L Treatment Not Containing Zolbetuximab Exposure - Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Not yet recruiting | Astellas Pharma Europe Ltd. | 1000 | 2027-01-31 | 2026-10-28 | |
| TRANScriptional Pathways Of Surgical Pain Modulated by Music Therapy Exposure (TRANSPOSE) Music-assisted relaxation and imagery (MARI) - Surgery, Stomach Cancer | Not applicable | Not yet recruiting | Case Comprehensive Cancer Center | 20 | 2027-01-01 | 2026-08-05 |
| Lymph Node Metastasis Pattern After Neoadjuvant Chemoimmunotherapy in LAGC Neoadjuvant SOX chemotherapy combined with PD-1 inhibitor - Stomach Neoplasms, Gastric Cancer (Diagnosis) | Not yet recruiting | Hainan General Hospital | 103 | 2027-01-01 | 2026-10-28 | |
| Axatilimab + CAR-T for High-Risk Lymphoma Axatilimab - Diffuse Large B Cell Lymphoma (DLBCL), Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma | Phase 1 | Not yet recruiting | Northside Hospital, Inc. | 29 | 2026-12-31 | 2026-10-16 |
| Disposable Endoscope Platform in Third Space Endoscopic Procedures (Esophageal or Gastric) Per-Oral Endoscopic Myotomy - Achalasia, Gastroparesis | Withdrawn | Baylor College of Medicine | 2026-12-30 | 2026-10-01 | ||
| Clinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastric Cancer Apatinib Mesylate Tablets - Gastric Cancer, Surgery | Phase 3 | Not yet recruiting | Fujian Medical University | 118 | 2026-12-25 | 2026-01-02 |
| Impact of Cryotherapy Spray (Tru-Freeze) for the Eradication of Gastric Antral Vascular Ectasia (ICE-GAVE) trūFreeze® Spray Cryotherapy System (STERIS Endoscopy) - Gastric Antral Vascular Ectasia | Not applicable | Recruiting | Mayo Clinic | 50 | 2026-12-22 | 2026-04-03 |
| Serplulimab, DOS and Lenvatinib Combine With PIPAC in the Oligometastatic Peritoneal Metastasis of Gastric/Gastroesophageal Junction Adenocarcinoma Serplulimab, Docetaxel, Oxaliplatin, S1, and Lenvatinib combined with PIPAC - Gastric/Gastroesophageal Junction Adenocarcinoma, Oligometastatic Peritoneal Metastasis | Phase 2 | Not yet recruiting | Fujian Cancer Hospital | 42 | 2026-12-15 | 2026-10-29 |
| Pilot Study of Salivary Bile Acids and Pepsin as Predictive Biomarkers of Reflux Disease After Sleeve Gastrectomy Reflux Disease, Gastro-Esophageal, Sleeve Gastrectomy | Not yet recruiting | Hospital de Mataró | 60 | 2026-12-01 | 2026-05-26 | |
| Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy Radical Gastrectomy with D2 Lymphadenectomy, Standard Systemic Therapy for Advanced Gastric Cancer - Gastric Cancer, Peritoneal Metastasis | Phase 3 | Recruiting | Hua Huang, MD, PhD | 170 | 2026-12-01 | 2026-10-16 |
| SND002 Cell Injection in Participants With Advanced Malignant Solid Tumors SND002 Cell Injection - Colorectal Neoplasms, Stomach Neoplasms | Phase 1 | Not yet recruiting | Guizhou Sinorda Pharmaceutical Co., Ltd. | 78 | 2026-12-01 | 2026-10-29 |
| A Study of Zolbetuximab Given With mFOLFOX6 or CAPOX Chemotherapy in Indian Adults With Gastric Cancer Zolbetuximab, Oxaliplatin, Folinic Acid - Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Phase 4 | Not yet recruiting | Astellas Pharma Global Development, Inc. | 50 | 2026-11-30 | 2026-09-21 |
| Zanidatamab Outcomes and Lived Experiences in Advanced HER2+ GEA Zanidatamab - Esophageal Cancer, GastroEsophageal Cancer | Not yet recruiting | Jazz Pharmaceuticals | 300 | 2026-11-30 | 2026-10-26 | |
| Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors REGN13089-M404-M2980 - Advanced Solid Tumors | Phase 1 / Phase 2 | Not yet recruiting | Regeneron Pharmaceuticals | 320 | 2026-11-23 | 2026-10-07 |
| Application of Intraperitoneal Hyperthermic Chemotherapy in the Treatment of Gastric Cancer With Peritoneal Metastasis Retlirafusp alfa + nab-paclitaxel + apatinib, HEPIC - Gastric Cancer (Diagnosis) | Phase 2 | Not yet recruiting | Anhui Provincial Cancer Hospital | 32 | 2026-11-20 | 2026-10-29 |
| A Trial of Pembrolizumab With Chemotherapy or Chemoradiotherapy in Participants From India With Different Types of Cancer (MK-3475-G44/KEYNOTE-G44) Pembrolizumab, Cisplatin, 5-Fluorouracil - Neoplasm Malignant, Gastric Neoplasms | Phase 4 | Not yet recruiting | Merck Sharp & Dohme LLC | 150 | 2026-11-06 | 2026-09-03 |
Showing 20 of 4039. Sign in to see all of them.
Stomach Neoplasms (3175) · Esophageal Neoplasms (561) · Pancreatic Neoplasms (405) · Colorectal Neoplasms (368) · Breast Neoplasms (301) · Gastroparesis (293) · Carcinoma, Non-Small-Cell Lung (232) · Ovarian Neoplasms (232) · Neoplasms (220) · Lung Neoplasms (203) · Colonic Neoplasms (199) · Carcinoma, Hepatocellular (152) · Neoplasm Metastasis (151) · Urinary Bladder Neoplasms (145) · Liver Neoplasms (144)
Digestive System Diseases (4018) · Gastrointestinal Diseases (4006) · Neoplasms by Site (3199) · Digestive System Neoplasms (3189) · Gastrointestinal Neoplasms (3106) · Neoplasms (3023) · Intestinal Diseases (945) · Pathological Conditions, Signs and Symptoms (890) · Esophageal Diseases (707) · Endocrine System Diseases (617) · Neoplasms by Histologic Type (600) · Head and Neck Neoplasms (566) · Endocrine Gland Neoplasms (557) · Intestinal Neoplasms (554)
Oxaliplatin (307) · Capecitabine (219) · Fluorouracil (192) · Cisplatin (174) · Docetaxel (144) · S 1 (combination) (139) · Paclitaxel (130) · Leucovorin (123) · Irinotecan (112) · pembrolizumab (112) · Trastuzumab (77) · Nivolumab (64) · apatinib (60) · Drug Therapy (53) · Esomeprazole (51)
Yonsei University (66) · National Cancer Institute (NCI) (64) · AstraZeneca (61) · Fudan University (53) · Fujian Medical University (47) · Memorial Sloan Kettering Cancer Center (39) · National Cancer Center, Korea (38) · Tianjin Medical University Cancer Institute and Hospital (36) · Samsung Medical Center (35) · Peking University (33) · Takeda (31) · The First Affiliated Hospital with Nanjing Medical University (30) · Chinese University of Hong Kong (29) · National Taiwan University Hospital (29) · Shanghai Zhongshan Hospital (29)
China (1173) · United States (1058) · South Korea (556) · Japan (229) · France (188) · United Kingdom (186) · Spain (183) · Italy (179) · Germany (175) · Taiwan (171) · Canada (145) · Australia (131) · Belgium (105) · Netherlands (90) · Poland (82)
Changming Huang, Professor (8) · Yelena Janjigian, MD (8) · Henry Parkman, MD (6) · Jiafu Ji, MD (6) · Lin Shen, MD (6)
PMID 35623069, PMID 40341124, PMID 20728210, PMID 40340830, PMID 15273542, PMID 19735233, PMID 20195905, PMID 33538338, PMID 33792646, PMID 38421211, PMID 21129076, PMID 22226517, PMID 24714327, PMID 30982686, PMID 35219300, PMID 35692051, PMID 37037952, PMID 38308771, PMID 38980664, PMID 39089261, PMID 40117530, PMID 11813623, PMID 16003309, PMID 16822992, PMID 17273960, PMID 17978289, PMID 17981197, PMID 18669424, PMID 18948798, PMID 19183157, PMID 19681809, PMID 21104822, PMID 21444866, PMID 22189752, PMID 22607579, PMID 23207683, PMID 23403142, PMID 23451835, PMID 23848826, PMID 24094768, PMID 24118079, PMID 24119887, PMID 24120337, PMID 24399492, PMID 24618998, PMID 25240821, PMID 25939684, PMID 26352529, PMID 26542081, PMID 26566136
2023 (29), 2017 (15), 2019 (13), 2018 (12), 2014 (11), 2015 (9), 2025 (9), 2016 (8), U01DK074007 (8), U01DK073974 (7), U01DK073975 (7), U01DK073983 (7), P30CA033572 (6), U01DK074035 (6), U01DK112193 (6)